Psilocybin
US Congress Adds Psychedelics Studies to Defense Bill
A bipartisan group of congressional lawmakers from both the House and the Senate have added funding for studies of psychedelic therapies into a major defense…
The psychedelic renaissance continues to gain legitimacy, supported by the most unlikely of allies — the United States military.
This week a bipartisan group of congressional lawmakers from both the House and the Senate have agreed to add funding for studies of psychedelic therapies into a major defense bill.
The 2024 National Defense Authorization Act (NDAA) passed on Wednesday and included the provision for psychedelics research introduced by Republican lawmakers like Rep. Morgan Luttrell of Texas.
The bill’s psychedelic sections require the Department of Defense (DOD) to facilitate access for military veterans to clinical trials for the treatment of PTSD or traumatic brain injury. The provisions allow for participating in studies using psilocybin, MDMA, ibogaine and 5-MeO-DMT (and “qualified plant-based alternative therapies”).
This isn’t a suggestion but a requirement, one that forces the Department of Defense to facilitate access for military service members, in addition to providing $10 million in funding, and partnerships with agencies and academic institutions doing psychedelic research.
Another major step forward for institutional acceptance of psychedelic therapies.
The times they are indeed a changing
For more on military support of psychedelics, check out Republican Lawmakers Introduce New Bill for Psychedelic Therapy
The post US Congress Adds Psychedelics Studies to Defense Bill appeared first on Microdose.
ibogaine psilocybin mdma dmt psychedelic psychedelic research therapy ptsd psychedelics funding authorization research-
Psychedelics1 week ago
MindBio Therapeutics Announces Landmark Women’s Health CNS Drug Trials
-
Psychedelics1 week ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Law & Regulation1 week ago
Compass Pathways, Journey Clinical to develop psilocybin treatment delivery model
-
Psychedelics1 week ago
Reunion Neuroscience Inc. Announces $103 Million Series A Financing Co-Led by MPM BioImpact and Novo Holdings
-
Psychedelics1 week ago
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
-
Ketamine1 week ago
DEA poised to move cannabis to Schedule III
-
Psychedelics1 week ago
Are ‘Ketamine Bros’ Ruining It for Everyone Else?
-
Psychedelics1 week ago
Behold! A New Mushroom Emoji Has Arrived!